Your browser doesn't support javascript.
loading
Incidence and survival for childhood cancer by endorsed non-stage prognostic indicators in Australia.
Youlden, Danny R; Gupta, Sumit; Frazier, A Lindsay; Moore, Andrew S; Gottardo, Nicholas G; Aitken, Joanne F.
Afiliación
  • Youlden DR; Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Queensland, Australia.
  • Gupta S; Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia.
  • Frazier AL; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Moore AS; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Gottardo NG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
  • Aitken JF; Oncology Service, Queensland Children's Hospital, Brisbane, Queensland, Australia.
Pediatr Blood Cancer ; 71(4): e30889, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38265260
ABSTRACT

BACKGROUND:

An international expert panel recently recommended 15 'non-stage prognostic indicators' (NSPIs) across eight childhood cancers, classified as essential or additional, for collection in population-based cancer registries. We aimed to describe the incidence distribution and survival of each of these NSPIs. PROCEDURES Cases were extracted from the Australian Childhood Cancer Registry. The study cohort (n = 4187) comprised all children aged under 15 years diagnosed with an eligible cancer between 2010 and 2018, with follow-up until 31 December 2020. NSPI data were collected directly from each patient's medical records. Differences in 5-year relative survival were assessed using multivariable flexible parametric models, adjusted for sex and age group at diagnosis.

RESULTS:

The availability of data varied, exceeding 85% for all essential NSPIs apart from histologic subtype for Wilms tumours (69%) and lineage for acute lymphoblastic leukaemia (78%). Information on additional NSPIs tended to be recorded less often, particularly cytogenetic subtype for non-alveolar rhabdomyosarcoma (28%) and astrocytoma (4%). Eight NSPIs exhibited a significant difference in survival, with the largest disparity occurring among children with astrocytoma according to tumour grade (5-year relative survival of 18% for grade IV disease compared with 99% for grade I disease; p < .001).

CONCLUSIONS:

Our findings demonstrate that most of the recommended NSPIs can be retrieved from medical records in Australia in recent years, allowing the capability of assessing survival within patient subgroups of clinical interest. Reporting of NSPI data has the capability to inform local and global understanding of population-level disparities in childhood cancer survival.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Astrocitoma / Neoplasias Renales / Neoplasias Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans / Infant País/Región como asunto: Oceania Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Astrocitoma / Neoplasias Renales / Neoplasias Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans / Infant País/Región como asunto: Oceania Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos